

Clinical Validation of ZiP-CoVx-P2 for COVID-19 point-of-care test in Ghana

(VaZico Study Ghana)

ACTRN12623000066684

Status	RECRUITING
Sponsor	ZiP Diagnostics Pty Ltd
Enrollment	1,000 participants

Plain Language Summary

Fast, accurate COVID-19 testing remains important even as the acute phase of the pandemic has passed — particularly in lower-resource settings where laboratory-based testing is difficult to access. This study is validating a new point-of-care molecular test called ZiP-CoVx-P2, which can detect the SARS-CoV-2 virus quickly without needing a central laboratory, much like a rapid antigen test but using more sensitive molecular technology.

The study is being conducted in Ghana, across hospitals and community health clinics in the Greater Accra and Central Regions. One thousand participants — both adults and children, with or without respiratory symptoms — will provide paired swab samples (throat and nasal). One swab will be tested with the new ZiP-CoVx-P2 device, and the other will be sent to a laboratory for the gold-standard PCR test. The results will be compared to establish how sensitive and specific the new test is.

You are eligible regardless of age or whether you currently have any symptoms. There are no exclusion criteria — the study is welcoming anyone attending the participating health facilities who is willing to provide informed consent (or whose parent/guardian consents on their behalf). This kind of diagnostic validation work is important for ensuring that new tests perform reliably before being deployed at scale.

Key Eligibility Criteria

Inclusion (1)

- All ages and genders, Participants with or without respiratory symptoms and Participants have provided informed consent.

Exclusion (1)

- None

Locations (1 total)

Ghana